Navigation Links
KEW Group Launches CancerPlex(SM) Assay to Bring State-of-the-Art Genomic Testing to Community Oncologists
Date:10/25/2013

c Therapeutic Pathways (KEW TPx). KEW MDx's CancerPlexSM test is the first of its diagnostic services designed to assist community oncologists in providing state-of-the-art genomic testing that previously has been available at large cancer treatment and academic centers. KEW is currently working with seven oncology practices in six different states to refine Therapeutic Pathways for seven types of cancer (breast, colorectal, lung, melanoma, lymphoma, thyroid and pancreatic). These seven practices all participate in a Center for Medicare and Medicaid Innovation Grant, which is developing and testing a Community Oncology Medical Home model, known as COME HOME. The grant is administered through Innovative Oncology Business Solutions, Inc., the organization that oversees and manages COME HOME. KEW's Treatment Pathways integrate newly emerging cancer genomic information that follows evidence standards essential to how and when to perform molecular tests, as well as inform care decisions. 

KEW Investor Contact:
Kathy Behrens Wilsey
Kathy@kewgroupllc.com


'/>"/>
SOURCE KEW Group Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Consolidation, Patent Loses, Weak R&D Productivity Depress ITO Transactions in Life Sciences Segment: Everest Group Annual Report
2. Polaris Group Files New IND for ADI-PEG 20 in Breast Cancer
3. WIRB-Copernicus Group Leaders Speak at Global Clinical Research Summit in South Korea
4. Global Stem Cells Group, Inc. Announces Worldwide Alliance with EmCyte Corp. to Promote In-office Regenerative Medicine Solutions
5. FarHawk Marketing Services Represents IonBench™ and MS Noise™ at the Greater Boston Mass Spectrometry Discussion Group Corporate Night October 3rd
6. Reimbursement Marketing Agency Element Marketing Group Inc. Opens New Office in Irvine, California
7. Dennis R. Hill, MD to Speak at the American Cancer Society Man-to-Man Support Group to Discuss HDR Brachytherapy for Prostate Cancer Treatment
8. Bangkok Hospital Group Selects ClinicalKey to Enhance Medical Practice and Improve Patient Care
9. The Arrow Group of Animal Hospitals in Central Arizona Partners with Vet-Stem, Inc. to Bring Stem Cell Therapy to Their Patients
10. Dennis R. Hill, MD to Speak at the American Cancer Society Man-to-Man Support Group to Discuss HDR Brachytherapy for Prostate Cancer Treatment
11. RGF Environmental Group Acquires AFL Industries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  The EveryLife ... Hatch (R-UT) and Amy Klobuchar ... Now Accelerating Cures & Treatments, or OPEN ACT. ... disease patient advocacy organizations, this bipartisan legislation promises ... affordable medicines to rare disease patients by incentivizing ...
(Date:5/21/2015)... 2015 As part of its philanthropic ... Sun Health Foundation funded a $3.25 million project to ... with the most up-to-date features and technology. , The ... pharmacy's 45 staff members will begin moving from the ... the coming days. , The current pharmacy has ...
(Date:5/20/2015)... Calif. , May 20, 2015 ... today presented preliminary data demonstrating the ability of ... pulmonary fibrosis (IPF) from other interstitial lung diseases ... suggest the classifier,s potential to help thousands of ... resolve ambiguity in IPF diagnosis – a frequent ...
(Date:5/20/2015)... 2015 The global genotyping market is ... the forecast period of 2015 to 2020 to reach ... in drug discovery and development process and to provide ... addition to this,heavy investments by key manufacturers to offer ... propelling market growth. Browse 113 market data tables & ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5
... chemists have developed a new model to predict the ... finding could help inform the design of tailored nano-structures, ... fields, including the remote sensing of atmospheric pollutants and ... nano-particles play a key role in atmospheric processes as ...
... Biotechnology, Inc. (OTC: CSBR) ("Champions") announced today the ... Inc. in which Champions will conduct low passage ... an inhibitor of mutant B-Raf, and CEP-37440, a ... determine the activity or response in potential clinical ...
... Health Diagnostic Laboratory, Inc. (HDL, Inc.) and BG Medicine, Inc. ... which HDL, Inc. will offer galectin-3 testing services based on ... Medicine Galectin-3 Test was recently cleared by the FDA as ... heart failure. Elevated galectin-3 levels are associated with an inherently ...
Cached Biology Technology:UBC researchers develop new model to predict the optical properties of nano-structures 2Champions Announces Technology Collaboration Utilizing Champions' Tumorgraft™ Technology Platform for Oncology Drug Development 2Champions Announces Technology Collaboration Utilizing Champions' Tumorgraft™ Technology Platform for Oncology Drug Development 3Health Diagnostic Laboratory, Inc. (HDL, Inc.) Announces Availability of Galectin-3 Testing Service in Partnership With BG Medicine 2Health Diagnostic Laboratory, Inc. (HDL, Inc.) Announces Availability of Galectin-3 Testing Service in Partnership With BG Medicine 3Health Diagnostic Laboratory, Inc. (HDL, Inc.) Announces Availability of Galectin-3 Testing Service in Partnership With BG Medicine 4
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
(Date:5/14/2015)... , May 14, 2015  Verificient Technologies, ... verification and online remote proctoring, announced a ... (SaaS) company and creator of the Canvas ... the two companies will benefit from the ... As a fully integrated multifactor ...
(Date:5/11/2015)... May 11, 2015 Curemark LLC, a privately ... of a new Phase III double blind, randomized, placebo-controlled ... formulation, CM-AT, on all children ages 3-8 with Autism. ... Phase III double blinded clinical trial for CM-AT in ... of the digestive enzyme chymotrypsin. This new trial will ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... a world-leading provider of scientific, technical and medical information products ... by the European Menopause and Andropause Society (EMAS) in journal ... postmenopausal women with summary recommendations. Vitamin D deficiency is ... is classified as a public health issue as it can ...
... billion-dollar-a-year industry in the United States that aims to create ... But a new analysis of restoration projects shows that restored ... "Once you degrade a wetland, it doesn,t recover its normal ... carbon, which both affect natural cycles of water and nutrients, ...
... hydrothermal sea vents go dormant and their blistering warmth turns to ... replaced. A team led by USC microbiologist Katrina Edwards found ... spewed by active hydrothermal vents are supplanted, once the vents go ... that make up the vents themselves. These findings based ...
Cached Biology News:Elsevier's Maturitas publishes position statement on the role of vitamin D in postmenopausal women 2Restored wetlands rarely equal condition of original wetlands 2Restored wetlands rarely equal condition of original wetlands 3Life discovered on dead hydrothermal vents 2
... media are rigid macroporous hydrophilic media. The ... at moderate pressures, while the macroporous beads ... hydrophilic matrix reduces nonspecific binding. Macro-Prep High ... exchanger with very high flow rates and ...
... collection of phage display libraries, human ... and mouse tissues. All cDNA libraries ... size of cDNA inserts has been ... 1000bp by gel electrophoresis of DNA ...
... Corticosterone kit is a competitive enzymeimmunoassay (EIA) ... mouse or rat serum or plasma. Corticosterone ... in rats and mice, and in most ... reptiles. Most mammals produce both corticosterone and ...
Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
Biology Products: